V ascular endothelial growth factor (VEGF), a 35-to 45-kDa homodimeric protein initially known as vascular permeability factor, is a potent stimulator of endothelial cell growth and neovascularization and has a strong permeability effect on vessels. [1] [2] [3] [4] The VEGF gene family consists of VEGF-A, -B, -C, and -D and placental growth factor (PlGF), which have different binding affinities for the three VEGF receptors (VEGFR). 5 VEGF, as it is classically known, refers to VEGF-A, which binds to VEGFR-1 and -2, which are primarily involved in angiogenesis. 6 -8 VEGF-A in turn has several isoforms of which VEGF 165 is one of the most abundant. 5 Increased VEGF levels in the vitreous of eyes with diabetic retinopathy, retinal vascular occlusions, and subretinal neovascularization have implicated VEGF as the major stimulus for intraocular neovascularization in these conditions. 9, 10 Bevacizumab is a humanized murine anti-VEGF monoclonal antibody that is specific to human VEGF and blocks all its isoforms, including VEGF 165 . 5, 11 Bevacizumab was developed for cancer treatment and has demonstrated improved survival in the treatment of metastatic colorectal cancer, advanced non-small-cell lung cancer and metastatic breast cancer. 12, 13 Recently, intravitreous bevacizumab has been used extensively for the treatment of macular edema and neovascularization in diseases such as diabetic retinopathy, age-related macular degeneration, retinal vein occlusion, neovascular glaucoma, and many other conditions. 14 -24 Several safety studies have reported the lack of toxicity of intravitreous bevacizumab in rabbits. [25] [26] [27] [28] However, more recent studies have demonstrated ultrastructural changes after intravitreous injection of bevacizumab in rabbits and primates. 29, 30 These previous toxicity studies have all injected bevacizumab into normal eyes. The purpose of our study was to evaluate the effects of intravitreous bevacizumab in an animal neovascularization model.
MATERIALS AND METHODS

Animals
All animal experiments were conducted in accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research and were approved by the Institutional Animal Care and Use Committee of the University of Southern California.
Twenty-four pigmented rabbits, weighing 2 to 3 kg, were used in the study. Only the right eye of each animal was used. Rabbits were assigned to five groups: groups A to D received intravitreous VEGF (recombinant human VEGF 165 ; Sigma-Aldrich, St. Louis, MO). Groups B, C, and D (n ϭ 5 each) received intravitreous bevacizumab (Avastin; Genentech Inc., San Francisco, CA) immediately after the VEGF injection, 2 days later, and 1 week later, respectively. Group A (n ϭ 4) did not receive any further injection and was used as the control. Group E (n ϭ 5), another control arm, received intravitreous bevacizumab only. The follow-up period was 3 weeks.
Intravitreous Injections
First, the rabbits were anesthetized with a subcutaneous injection of a mixture of ketamine hydrochloride (25 mg/kg) and xylazine hydrochloride (6 mg/kg). The pupils were dilated with topical application of phenylephrine hydrochloride 2.5% and tropicamide 0.5% eye drops.
Intravitreous injections were performed in sterile conditions and after instillation of several drops of 5% povidone iodine. Topical tetra-caine drops were applied for additional anesthesia. A speculum was used to keep the eyelids open, and the procedure was performed under direct visualization using an operating microscope and a surgical contact lens. A 27-gauge needle attached to a 1-mL syringe was introduced into the vitreous cavity transconjunctivally, at the superotemporal quadrant, 1.5 mm behind the limbus. If the total volume of the intravitreous drugs to be injected was to be more than 0.05 mL (i.e., as in group B), the same volume of vitreous was first withdrawn to prevent extravasation of the drug from the injection site. Intravitreous injection was then performed from the same port, using another 27-gauge needle and a 1-mL syringe. In group B, which received VEGF and bevacizumab at the same time, bevacizumab was injected from a different port, at the superonasal quadrant, 1.5 mm behind the limbus. The amount of VEGF injected was 10 g in 0.01 mL and that of bevacizumab was 1.25 mg in 0.05 mL. At the end of the procedure, topical antibiotic ointment (Neo-Poly-Bac; Bausch & Lomb Inc., Tampa, FL) was applied.
Follow-up Examinations
Examinations included evaluation of the anterior segment by surgical microscope, color fundus photography, fluorescein angiography (FA), and optical coherence tomography (OCT). Before each session, the rabbits were anesthetized, and the pupils were dilated as explained earlier. Baseline examinations were performed within a week before the first intravitreous injection, and follow-up examinations were performed at day 2 and weeks 1, 2, and 3 after the first injection.
Color Fundus Photography. A digital fundus camera system (model FF 450 IR; Carl Zeiss, Jena, Germany) was used to take at least five photographs in each eye: optic disc, temporal medullary wing, nasal medullary wing, superior retina above the disc, and inferior retina below the disc.
Fluorescein Angiography. The same digital fundus camera system used for color fundus photography was set for FA by selecting the appropriate filters. An intravenous line was established on the marginal ear vein and 0.2 mL of 10% fluorescein was injected and flushed with 1 mL of normal saline. Sequential fundus photographs were taken immediately after fluorescein injection. Late photographs were taken at 3 and 5 minutes. In selected cases anterior segment photographs were taken as well.
In cases in which there was capillary nonperfusion, it was classified as mild, moderate, or severe, based on the extent of capillary closure. When there were only patches of capillary nonperfusion, it was classified as mild. In cases in which the capillary nonperfusion was continuous and involved both medullary wings, it was classified as moderate when less than 50% of capillaries were closed and severe when more than 50% were closed.
Optical Coherence Tomography.
With an OCT system (Stratus system; ver. 4.0 software; Carl Zeiss Meditec, Inc., Dublin, CA), 5-mm radial line scans were taken at the medullary wings and below the optic disc.
Histopathology
At the end of the last follow-up examination in each group, the rabbits were euthanatized by intracardiac injection of 2 mL pentobarbital (Beuthanasia-D; Schering Plough Animal Health, Omaha, NE). The eyes were enucleated and immersed in Davidson's fixative solution for 16 to 24 hours and then dehydrated in a series of graded alcohol solutions in the next 24 to 48 hours before paraffin embedding. Blocks were obtained from cuts through the whole globe, oriented perpendicular to the medullary wings. Sections 5 m thick obtained by a microtome were stained with hematoxylin and eosin (H&E) and examined by light microscopy.
RESULTS
Intravitreous injection of VEGF was invariably associated with disc hyperemia, vascular dilatation and tortuosity, and fluorescein leakage at the optic disc, medullary wings and anterior chamber (AC) at day 2 ( Table 1 In group A, which was kept as control, there was no leakage at the optic disc or in the AC at week 2 (Fig. 3) . In addition, no neovascular membrane was visible on color fundus photography or FA (Fig. 1) . OCT, however, showed thinning of the epiretinal membrane (Fig. 2) . At this time, the optic disc and medullary wings were pale, the retinal surface at medullary wings near the optic disc was irregularly elevated, the vascular pattern was irregular, and there was vascular narrowing in some cases. At week 3, there was no significant change, except that horizontal retinal folds appeared at the upper and lower edges of the medullary wings. There was mild to moderate capillary nonperfusion in all cases (Table 1, Fig. 4) .
In group B, in which bevacizumab was injected at the same time as VEGF, no leakage occurred at the optic disc or in the AC at day 2 or beyond, but the retinal vessels became mildly dilated, and tortuous and retinal capillaries became prominent (Table 1 ; Figs. 1, 3) . Vascular dilatation and tortuosity diminished slightly at week 3 but was not completely resolved.
In group C, in which bevacizumab was injected 2 days after VEGF, there was no leakage at the optic disc or in the AC at week 1 or beyond, nor was there formation of any neovascular membrane. There was, however, mild vascular dilatation and tortuosity, and prominence of the retinal capillaries (Table 1; Figs. 1, 3). Vascular dilatation and tortuosity diminished slightly at week 3 but was not completely resolved.
In group D, in which bevacizumab was injected 1 week after VEGF, color fundus photography and FA findings were similar to those in group A at week 2, except that the capillary nonperfusion was severe in four of the five animals in this group (Table 1, Figs. 1, 3, 4) .
Group E, which received intravitreous bevacizumab only, did not show any abnormalities in color fundus photography or FA over time (Figs. 1, 3) .
In groups A and D there was epiretinal fibrosis over the medullary wings in all cases (Fig. 5) . The membrane was associated with retinal folds at the upper and lower edges of the medullary wing. Groups B and C showed vascular crowding over the medullary wings. Group E did not display any abnormality.
DISCUSSION
Several investigators have created retinal neovascularization in rabbits using sustained-release pellets loaded with VEGF with or without basic fibroblast growth factor (bFGF). [31] [32] [33] In our study, however, we used a simpler retinal neovascularization FIGURE 3. FA images in groups A to E. Each column shows changes in FA of a representative rabbit in each group with time. Images were taken 20 to 40 seconds after fluorescein injection. Group A: leakage at disc and medullary wings at day 2, neovascular membrane at week 1, and lack of leakage or neovascular membrane at week 2. Also, note patches of capillary nonperfusion at week 2 (thick arrow). Group B: prominence of capillaries and lack of leakage at day 2, week 1, and week 2. Group C: leakage at day 2, prominence of capillaries as well as lack of leakage and neovascular membrane at weeks 1 and 2. Group D: leakage at disc and medullary wings at day 2, neovascular membrane at week 1, lack of leakage or neovascular membrane at week 2, and widespread capillary nonperfusion at week 2 (thin arrows). Group E: normal FA throughout the study period.
Š FIGURE 1. Color fundus images in groups A to E. Images in each column show changes in fundus appearance of a representative rabbit in each group with time. Group A: disc hyperemia and vascular dilatation and tortuosity at day 2, neovascular membrane at week 1, and mild disc and medullary wing pallor and irregular vascular pattern at week 2. Group B: mild vascular dilatation and tortuosity at day 2 and week 1 and, to a lesser extent, at week 2. Group C: disc hyperemia and vascular dilatation at day 2 and vascular dilatation and tortuosity at week 1 and, to a lesser extent, at week 2. Group D: disc hyperemia and vascular dilatation at day 2, neovascular membrane at week 1, and pallor of disc and medullary wings and narrowing of blood vessels at week 2. Group E: normal fundus appearance throughout the study period.
FIGURE 2.
OCT in groups A, B, C, and D. All scans are along a line at the edge of the optic disc, perpendicular to the medullary wing. Group A: dilated vessels at day 2, epiretinal thickening at week 1, and decreased thickening at week 2. Group B: dilated vessels at day 2 and weeks 1 and 2. Group C: dilated vessels at day 2 and weeks 1 and 2. Group D: dilated vessels at day 2, epiretinal thickening at week 1, and decreased thickening at week 2. When bevacizumab was injected at the same time as VEGF or 2 days later, retinal neovascularization was prevented. In addition, bevacizumab treatment was able to prevent or stop leakage both at the disc and in the AC. However, it was not able to prevent or reverse vascular dilatation and tortuosity completely. Some investigators have speculated that the amount and duration of VEGF exposure necessary for bloodretina barrier breakdown may be less than that for neovascularization.
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6,34 Our study did not support or reject this idea. However, assuming that vascular dilatation and tortuosity could be a part of early stage of neovascularization, it may be that the amount of VEGF required for initiation of neovascularization is less than that for blood-retina barrier breakdown.
Little is known about the role of VEGF in the maintenance of adult ocular vasculature. Although some studies have indicated that VEGF maintains normal vasculature in the respiratory system of mice and rats, a study of adult mice did not find the normal retinal vasculature to be dependent on VEGF. 5, [35] [36] [37] On the other hand, it has been shown that VEGF withdrawal can lead to the regression of the newly grown vessels but not the more established ones. 6, 38 In our study, in the positive control group (group A), intravitreous injection of VEGF resulted in formation of a neovascular membrane at week 1. However, at week 2, the membrane became avascular, and in addition, there was mild to moderate nonperfusion of normal capillaries. Injection of bevacizumab 1 week after VEGF injection (group D) was associated with more extensive nonperfusion and closure of normal capillaries at week 2. It seems that after week 1, there was a reverse correlation between the effective VEGF concentration and the extent of capillary nonperfusion. In other words, blockage of the remaining VEGF by bevacizumab resulted in a sudden decrease in effective VEGF concentration and consequently a more extensive capillary nonperfusion.
Repeated intravitreous injection of VEGF in primates has been shown to be associated with retinal capillary nonperfusion secondary to endothelial cell hyperplasia and hypertrophy. 34, 39, 40 However, no capillary nonperfusion has been observed after a single intravitreous injection of VEGF. 34 In our study, capillary nonperfusion occurred between the first and second weeks after a single intravitreous VEGF injection, when the VEGF concentration was falling. This observation suggests that normal vessels may become VEGF dependent when suddenly exposed to a high concentration of VEGF. It seems a certain amount of VEGF is necessary to maintain the newly grown vessels as well as normal, but now sensitized, capillaries. When the effective VEGF concentration declines below this putative threshold, it may result in regression of the new vessels and closure of normal capillaries.
The mechanism by which normal capillaries become VEGF dependent is not clear. Although downregulation of VEGF receptors in endothelial cells may play a role, it is plausible that the strong VEGF drive causes sprouting of numerous new vessels from the normal capillaries such that normal capillaries transform and become part of the architecture of the neovascular membrane and hence VEGF dependent. This possibility is supported by the FA at week 1 which illustrates that the majority of normal capillaries are indistinguishable from the newly formed vessels within the neovascular membrane (Fig. 3) .
Vascular response to anti-VEGF therapy appears to be related to the degree of vessel maturity (e.g., presence of pericytes and vascular smooth muscle cells around capillaries and larger vessels, respectively). 41, 42 Mural cell recruitment to endothelial cells requires a signaling process involving plateletderived growth factor (PDGF)-B, produced by endothelial cells, and PDGF receptor (PDGFR)-␤, carried by mural cells or undifferentiated mesenchymal cells. 43 Tumor vessels lacking mural cells are more sensitive to VEGF-A withdrawal-induced apoptosis. 42 Thus, more mature vessels may be less sensitive to anti-VEGF-A therapy. In animal models of choroidal neovascularization (CNV), combined inhibition of VEGF-A and PDGF-B signaling pathways via pegaptanib and an antibody against PDGFR-␤, respectively, synergistically inhibits CNV growth. 44 Although further studies are necessary to elucidate the mechanisms of the observed phenomenon, the significant nonperfusion observed in this study would raise concerns regarding the use of anti-VEGF therapy in states in which high levels of VEGF are present (e.g., in diseases with severe retinal ischemia). Thus, until additional data are available, judicious use of anti-VEGF drugs such as bevacizumab and ranibizumab may be warranted in cases of acute and severe retinal neovascularization, to prevent capillary nonperfusion and further retinal ischemia. The significance of the findings of the present study, however, is limited by the nature of the animal model (the merangiotic rabbit retina), in which the retinal vasculature is on the surface of the retina and not within the retina as in humans. The relevance to human retinal vascular disease remains uncertain until these results can be confirmed in other model systems. Another limitation of our study is that the experimental pathology is solely induced by VEGF 165 which is believed to be the predominant factor but not the only VEGF isoform involved in neovascular diseases. Indeed, VEGF 121 , although less abundant, is more mitogenic than VEGF 165 . 45 In addition, all other VEGF-A isoforms theoretically may be cleaved by plasmin to generate VEGF 110 , which can stimulate endothelial cell growth and induce vascular permeability. 5,46 -48 From a different perspective, the observed phenomenon in our study could be used to sensitize established new vessels to antiangiogenesis drugs by exposing them to a high dose of VEGF. This method of sensitization may be of use in treating established neovascular membranes and ocular or systemic tumors.
Histopathologic examination of the enucleated eyes showed epiretinal fibrosis after disappearance of neovascular membranes in groups A and D. This finding is consistent with the clinical outcome observed in patients with proliferative diabetic retinopathy treated by laser photocoagulation or intravitreous bevacizumab and with a histopathological report of a human case of choroidal neovascular membrane treated by intravitreous bevacizumab. 49, 50 In conclusion, intravitreous injection of VEGF resulted in formation of a neovascular membrane at week 1, followed by regression of the new vessels and mild to moderate closure of normal capillaries at week 2. Early intravitreous injection of bevacizumab (at the same time as VEGF injection or two days later) was able to prevent or stop leakage both at the disc and in the AC but was not able to prevent or reverse vascular dilatation and tortuosity completely, indicating that a lower dose of VEGF may be necessary for initiation of neovascularization than for blood-retina barrier breakdown. Of importance, late injection of bevacizumab (1 week after VEGF injection) resulted in severe closure of normal capillaries. This effect may be due to normal capillaries becoming VEGF dependent when suddenly exposed to a high dose of VEGF. Thus, in treating patients with acute or severe retinal neovascularization with anti-VEGF drugs such as bevacizumab, caution may be warranted to prevent capillary nonperfusion and macular ischemia. Further studies are needed to evaluate the possibility of sensitizing established neovascular membranes or established new vessels in ocular or systemic tumors to antiangiogenesis drugs by exposing them to a high dose of growth factors such as VEGF.
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